Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP 13C-aKG Metabolic Imaging in IDH Mutant Glioma
NCT05851378Phase 1Completed
- Start
- Apr 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of hyperpolarized carbon 13 alpha-ketoglutarate in glioma (2 cohorts). Primary endpoints: Mean signal to noise ratio of HP 13C-aKG at 1 day, Mean signal to noise ratio of oncometabolite 2-hydroxyglutarate (2-HG) at 1 day and 7 more. Started Apr 2023; status: completed.
02
Drugs
hyperpolarized carbon 13 alpha-ketoglutarate
03
Conditions
glioma
Beyond the preview
Go deeper on NCT05851378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05851378.